Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Risk Assessment for Tobacco Regulation.

Berman ML, El-Sabawi T, Shields PG.

Tob Regul Sci. 2019 Jan;5(1):36-49. doi: 10.18001/TRS.5.1.4.

PMID:
31602391
2.

The Role of Advocacy in Public Health Law.

Berman ML, Tobin-Tyler E, Parmet WE.

J Law Med Ethics. 2019 Jun;47(2_suppl):15-18. doi: 10.1177/1073110519857308.

PMID:
31298130
3.

Closing the Regulatory Gap for Synthetic Nicotine Products.

Zettler PJ, Hemmerich N, Berman ML.

Boston Coll Law Rev. 2018;59(6):1933-1982. Epub 2018 Jul 11.

4.

The Supreme Court's Crisis Pregnancy Center Case - Implications for Health Law.

Parmet WE, Berman ML, Smith JA.

N Engl J Med. 2018 Oct 18;379(16):1489-1491. doi: 10.1056/NEJMp1809488. Epub 2018 Aug 29. No abstract available.

PMID:
30156965
5.

Anticipating Industry Arguments: The US Food and Drug Administration's Authority to Reduce Nicotine Levels in Cigarettes.

Berman ML, Zettler PJ, Ashley DL.

Public Health Rep. 2018 Jul/Aug;133(4):502-506. doi: 10.1177/0033354918776935. Epub 2018 Jun 7.

6.

Para-ovarian adrenal rest tumors: gynecologic manifestations of untreated congenital adrenal hyperplasia.

Sisto JM, Liu FW, Geffner ME, Berman ML.

Gynecol Endocrinol. 2018 Aug;34(8):644-646. doi: 10.1080/09513590.2018.1441399. Epub 2018 Feb 20.

PMID:
29460643
7.

Attitudes toward Tobacco, Alcohol, and Non-Alcoholic Beverage Advertisement Themes among Adolescent Boys.

Friedman KL, Roberts ME, Keller-Hamilton B, Yates KA, Paskett ED, Berman ML, Slater MD, Lu B, Ferketich AK.

Subst Use Misuse. 2018 Aug 24;53(10):1706-1714. doi: 10.1080/10826084.2018.1429473. Epub 2018 Feb 13.

8.

Communicating Tobacco Product Information to the Public.

Berman ML, Byron MJ, Hemmerich N, Lindblom EN, Lazard AJ, Peters E, Brewer NT.

Food Drug Law J. 2017;72(3):386-405.

9.

Young Adult Perceptions Surrounding Hookah Use.

Roberts ME, Klein EG, Berman ML, Berhane B, Ferketich AK.

Health Behav Policy Rev. 2017 Nov;4(6):593-600. doi: 10.14485/HBPR.4.6.9.

10.

FDA-Required Tobacco Product Inserts & Onserts–and the First Amendment.

Lindblom EN, Berman ML, Thrasher JF.

Food Drug Law J. 2017;72(1):1-25.

11.

Consortium on Methods Evaluating Tobacco: Research Tools to Inform US Food and Drug Administration Regulation of Snus.

Berman ML, Bickel WK, Harris AC, LeSage MG, O'Connor RJ, Stepanov I, Shields PG, Hatsukami DK.

Nicotine Tob Res. 2018 Sep 25;20(11):1292-1300. doi: 10.1093/ntr/ntx228. Review.

12.

Reducing tobacco-related harm: FDA's proposed product standard for smokeless tobacco.

Berman ML, Hatsukami DK.

Tob Control. 2018 May;27(3):352-354. doi: 10.1136/tobaccocontrol-2016-053612. Epub 2017 Jun 20.

13.

Consumers' Preferences for Electronic Nicotine Delivery System Product Features: A Structured Content Analysis.

Kistler CE, Crutchfield TM, Sutfin EL, Ranney LM, Berman ML, Zarkin GA, Goldstein AO.

Int J Environ Res Public Health. 2017 Jun 7;14(6). pii: E613. doi: 10.3390/ijerph14060613.

14.

Medicaid Expansion and ACA Repeal: Evidence From Ohio.

Seiber EE, Berman ML.

Am J Public Health. 2017 Jun;107(6):889-892. doi: 10.2105/AJPH.2017.303722. Epub 2017 Apr 20.

15.

E-Cigarettes, Youth, and the US Food and Drug Administration's "Deeming" Regulation.

Berman ML, Yang YT.

JAMA Pediatr. 2016 Nov 1;170(11):1039-1040. doi: 10.1001/jamapediatrics.2016.2255. No abstract available.

PMID:
27668949
16.

FDA's misplaced priorities: premarket review under the Family Smoking Prevention and Tobacco Control Act.

Jenson D, Lester J, Berman ML.

Tob Control. 2016 May;25(3):246-53. doi: 10.1136/tobaccocontrol-2015-052391. Epub 2016 Apr 11.

PMID:
27068243
17.

Raising the Tobacco Sales Age to 21: Surveying the Legal Landscape.

Berman ML.

Public Health Rep. 2016 Mar-Apr;131(2):378-81. No abstract available.

18.

Providing a Science Base for the Evaluation of Tobacco Products.

Berman ML, Connolly G, Cummings KM, Djordjevic MV, Hatsukami DK, Henningfield JE, Myers M, O'Connor RJ, Parascandola M, Rees V, Rice JM, Shields PG.

Tob Regul Sci. 2015 Apr;1(1):76-93.

19.

Point-of-sale tobacco marketing in rural and urban Ohio: Could the new landscape of Tobacco products widen inequalities?

Roberts ME, Berman ML, Slater MD, Hinton A, Ferketich AK.

Prev Med. 2015 Dec;81:232-5. doi: 10.1016/j.ypmed.2015.08.024. Epub 2015 Sep 9.

20.

Bridging the gap between science and law: the example of tobacco regulatory science.

Berman ML, Kim AE.

J Law Med Ethics. 2015 Spring;43 Suppl 1:95-8. doi: 10.1111/jlme.12227. No abstract available.

21.

Commercial speech law and tobacco marketing: a comparative discussion of the United States and Canada.

Berman ML.

Am J Law Med. 2013;39(2-3):218-36. No abstract available.

PMID:
23815029
22.

Who's your nanny? Choice, paternalism and public health in the age of personal responsibility.

Wiley LF, Berman ML, Blanke D.

J Law Med Ethics. 2013 Mar;41 Suppl 1:88-91. doi: 10.1111/jlme.12048.

PMID:
23590750
23.

The growing role of web-based geospatial technology in disaster response and support.

Kawasaki A, Berman ML, Guan W.

Disasters. 2013 Apr;37(2):201-21. doi: 10.1111/j.1467-7717.2012.01302.x. Epub 2012 Dec 27. Review.

PMID:
23278379
24.

A public health perspective on health care reform.

Berman ML.

Health Matrix Clevel. 2011;21(2):353-83. No abstract available.

PMID:
22145521
25.

Role of adjuvant chemotherapy in patients with early stage uterine papillary serous cancer.

Mahdavi A, Tajalli TR, Dalmar A, Vasilev SA, Lentz SE, Berman ML.

Int J Gynecol Cancer. 2011 Nov;21(8):1436-40. doi: 10.1097/IGC.0b013e31822e7588.

PMID:
21997174
26.

From health care reform to public health reform.

Berman ML.

J Law Med Ethics. 2011 Fall;39(3):328-39. doi: 10.1111/j.1748-720X.2011.00603.x.

PMID:
21871031
27.

Fertility preserving options in patients with gynecologic malignancies.

Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE.

Am J Obstet Gynecol. 2011 Aug;205(2):103-10. doi: 10.1016/j.ajog.2011.01.025. Epub 2011 Mar 16. Review.

28.

Surgical management of recurrent ovarian cancer: the advantage of collaborative surgical management and a multidisciplinary approach.

Burton E, Chase D, Yamamoto M, de Guzman J, Imagawa D, Berman ML.

Gynecol Oncol. 2011 Jan;120(1):29-32. doi: 10.1016/j.ygyno.2010.10.008. Epub 2010 Nov 4.

PMID:
21055797
29.

Preoperative diagnosis of ovarian malignancy: preliminary results of the use of 3-dimensional vascular ultrasound.

Chase DM, Crade M, Basu T, Saffari B, Berman ML.

Int J Gynecol Cancer. 2009 Apr;19(3):354-60. doi: 10.1111/IGC.0b013e3181a1d73e.

PMID:
19407559
30.

Sclerosing ductal carcinoma of the clitoris with microcystic adnexal carcinoma-like features.

DuPont NC, Mabuchi S, Ries S, Berman ML.

J Cutan Pathol. 2009 Mar;36(3):359-61. doi: 10.1111/j.1600-0560.2008.01044.x.

PMID:
19220633
31.

Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis.

Chan JK, Sugiyama V, Pham H, Gu M, Rutgers J, Osann K, Cheung MK, Berman ML, Disaia PJ.

Gynecol Oncol. 2007 Mar;104(3):636-41. Epub 2006 Nov 7.

PMID:
17095080
32.

Influence of serum and tissue micronutrient levels on the regression of untreated cervical intraepithelial neoplasia 2 and 3.

McHale MT, Berman ML, Keefe KA, Schell MJ, Peng YM, Monk BJ.

J Low Genit Tract Dis. 2002 Oct;6(4):220-4.

PMID:
17051026
33.

Malignant eccrine spiradenoma of the vulva: a case report and review of the literature.

Chase DM, Basu T, Saffari B, Ries S, Berman ML.

Int J Gynecol Cancer. 2006 May-Jun;16(3):1465-9. Review.

PMID:
16803551
34.

The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma.

Hamilton CA, Cheung MK, Osann K, Balzer B, Berman ML, Husain A, Teng NN, Kapp DS, Chan JK.

Gynecol Oncol. 2006 Nov;103(2):679-83. Epub 2006 Jun 21.

PMID:
16793126
35.

Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma.

Hamilton CA, Liou WS, Osann K, Berman ML, Husain A, Teng NN, Kapp DS, Chan JK.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):839-44.

PMID:
16199314
36.

Patients with malignancy requiring urgent therapy: CASE 3. Tumor lysis syndrome associated with chemotherapy in ovarian cancer.

Chan JK, Lin SS, McMeekin DS, Berman ML.

J Clin Oncol. 2005 Sep 20;23(27):6794-5. No abstract available.

PMID:
16170188
37.

Clinicopathologic features of six cases of primary cervical lymphoma.

Chan JK, Loizzi V, Magistris A, Hunter MI, Rutgers J, DiSaia PJ, Berman ML.

Am J Obstet Gynecol. 2005 Sep;193(3 Pt 1):866-72. Review.

PMID:
16150291
38.

Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.

Tewari KS, Mehta RS, Burger RA, Yu IR, Kyshtoobayeva AS, Monk BJ, Manetta A, Berman ML, Disaia PJ, Fruehauf JP.

Gynecol Oncol. 2005 Sep;98(3):360-8.

39.

Surgical management of epithelial ovarian cancer: a review of the literature.

Dupont NC, Berman ML.

Minerva Ginecol. 2004 Dec;56(6):547-56. Review.

PMID:
15729207
40.

Validation of referral guidelines for women with pelvic masses.

Im SS, Gordon AN, Buttin BM, Leath CA 3rd, Gostout BS, Shah C, Hatch KD, Wang J, Berman ML.

Obstet Gynecol. 2005 Jan;105(1):35-41.

PMID:
15625139
41.

Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer.

Chan JK, Loizzi V, Magistris A, Lin F, Rutgers J, Osann K, Disaia PJ, Berman ML.

Clin Cancer Res. 2004 Dec 15;10(24):8538-43.

42.

Surgical cytoreduction and hormone therapy of an advanced endometrial stromal sarcoma of the ovary.

Geas FL, Tewari DS, Rutgers JK, Tewari KS, Berman ML.

Obstet Gynecol. 2004 May;103(5 Pt 2):1051-4.

PMID:
15121605
43.

Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a U.S. case-control study.

Lacey JV Jr, Potischman N, Madigan MP, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lurain JR, Fillmore CM, Sherman ME, Brinton LA.

Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):607-12.

44.

Adjuvant radiotherapy following properly staged endometrial cancer: what role?

Berman ML.

Gynecol Oncol. 2004 Mar;92(3):737-9. No abstract available.

PMID:
14984934
45.

Oral altretamine used as salvage therapy in recurrent ovarian cancer.

Chan JK, Loizzi V, Manetta A, Berman ML.

Gynecol Oncol. 2004 Jan;92(1):368-71.

PMID:
14751188
46.

Modified technique for suprapubic catheter insertion that avoids urinary leakage.

Berman ML, Truong TH, DiSaia PJ, Chan JK.

Am J Obstet Gynecol. 2003 Dec;189(6):1670-1.

PMID:
14710096
47.

Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy.

Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML.

Am J Obstet Gynecol. 2003 Nov;189(5):1301-7.

PMID:
14634558
48.

Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome.

Chan JK, Lin YG, Loizzi V, Ghobriel M, DiSaia PJ, Berman ML.

J Reprod Med. 2003 Oct;48(10):756-60.

PMID:
14619640
49.

HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3.

Chan JK, Monk BJ, Brewer C, Keefe KA, Osann K, McMeekin S, Rose GS, Youssef M, Wilczynski SP, Meyskens FL, Berman ML.

Br J Cancer. 2003 Sep 15;89(6):1062-6.

50.

Future directions in the surgical management of ovarian cancer.

Berman ML.

Gynecol Oncol. 2003 Aug;90(2 Pt 2):S33-9. Review.

PMID:
12928004

Supplemental Content

Loading ...
Support Center